Kiniksa Pharmaceuticals
↗London, United Kingdom
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company's primary focus is on cardiovascular and autoimmune indications, leveraging its expertise in the interleukin-1 (IL-1) pathway.
The company's lead product, ARCALYST (rilonacept), is the first and only FDA-approved therapy for recurrent pericarditis. Kiniksa is also advancing a pipeline of next-generation monoclonal antibodies, including KPL-387 and KPL-1161, which target the IL-1 receptor to provide potentially more convenient dosing options for chronic inflammatory conditions.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Cardiovascular and Autoimmune Therapeutics
SIZE & FINANCIALS
Employees:201-500
Revenue:$500M-$1B
Founded:2015
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$80M+
Investors:Baker Bros. Advisors, HBM Healthcare Investments, Qatar Investment Authority
STOCK
Exchange:NASDAQ
Ticker:KNSA
Market Cap:$3.44B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (ARCALYST)
Modalities:mAb, Fusion protein, Cytokine trap
Active Trials:8
Trial Phases:Phase 1: 2 | Phase 2: 3 | Phase 3: 1 | Phase 4: 2
FDA Approvals:3
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Kiniksa Pharmaceuticals Corp., Kiniksa Pharmaceuticals, GmbH, Kiniksa Pharmaceuticals (UK), Ltd.
Key Partnerships:Regeneron (License for ARCALYST), Samsung Biologics (Manufacturing partner), Huadong Medicine (Strategic collaboration for Asia-Pacific)
COMPETITION
Position:Leader
Competitors:Sobi, Sanofi, Regeneron, Novartis, SpringWorks Therapeutics
LEADERSHIP
Key Executives:
Sanj K. Patel - CEO & Chairman
Ross Moat - Chief Operating Officer
Scientific Founders:Sanj K. Patel
Board Members:Felix Baker, Stephen Biggar, Kimberly Popovits, Richard Levy
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kiniksa Pharmaceuticals. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.